Adage Capital Partners
OVID icon

Adage Capital Partners’s Ovid Therapeutics OVID Stock Holding History

Adage Capital Partners’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6M Hold
6,163,781
– – 0.02% 572
2026
Q1 		$13.7M Buy
6,163,781
+2,671,781
+77% +$4.78M 0.02% 597
2025
Q4 		$5.69M Buy
3,492,000
+2,142,000
+159% +$3.3M 0.01% 744
2025
Q3 		$1.75M Buy
1,350,000
+200,000
+17% +$173K ﹤0.01% 814
2025
Q2 		$379K Hold
1,150,000
– – ﹤0.01% 816
2025
Q1 		$359K Buy
1,150,000
+150,000
+15% +$92.2K ﹤0.01% 818
2024
Q4 		$934K Buy
+1,000,000
New +$1.12M ﹤0.01% 821

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Adage Capital Partners's OVID Position: Q2 2026 in Review

Adage Capital Partners held its Ovid Therapeutics (OVID) position steady in Q2 2026 at 6,163,781 shares worth $16.6M. The position accounts for 0.02% of the portfolio, ranked #572.

Adage Capital Partners first reported a position in OVID in Q4 2024 and has held it in 7 quarters since. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Adage Capital Partners held 6,163,781 shares of Ovid Therapeutics worth $16.6M as of Q2 2026.
  • Adage Capital Partners left its Ovid Therapeutics share count unchanged in Q2 2026.
  • Ovid Therapeutics made up 0.02% of Adage Capital Partners's portfolio in Q2 2026, its #572 holding.
  • Adage Capital Partners first reported a position in Ovid Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.